2-(4-bromo-1H-indol-3-yl)-2-oxoacetyl chloride | 960148-53-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-(4-bromo-1H-indol-3-yl)-2-oxoacetyl chloride
• CAS: 960148-53-2
• 化学式: C₁₀H₅BrClNO₂
• 分子量: 286.512
• InChiKey: RARGIHXLDQYZKR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-bromo-1H-indol-3-yl)-2-oxoacetyl chloride 在 lithium aluminium tetrahydride 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 4-bromo-3-(p-toluenesulfonyloxyethyl)-1-(p-toluenesulfonyl)indole
  参考文献：
  名称：

  Structure−Activity Relationships of 2,N⁶,5‘-Substituted Adenosine Derivatives with Potent Activity at the A_2B Adenosine Receptor

  摘要：

  2, N-6, and 5'-substituted adenosine derivatives were synthesized via alkylation of 2-oxypurine nucleosides leading to 2-arylalkylether derivatives. 2-(3-(Indolyl)ethyloxy)adenosine 17 was examined in both binding and cAMP assays and found to be a potent agonist of the human A(2B)AR. Simplification, altered connectivity, and mimicking of the indole ring of 17 failed to maintain A2BAR potency. Introduction of N-6-ethyl or N-6-guanidino substitution, shown to favor A2BAR potency, failed to enhance potency in the 2-( 3-( indolyl)ethyloxy) adenosine series. Indole 5 ''- or 6 ''-halo substitution was favored at the A(2B)AR, but a 5'-N-ethylcarboxyamide did not further enhance potency. 2-(3 ''-(6 ''-Bromoindolyl)ethyloxy)adenosine 28 displayed an A(2B)AR EC50 value of 128 nM, that is, more potent than the parent 17 (299 nM) and similar to 5'-N-ethylcarboxamidoadenosine (140 nM). Compound 28 was a full agonist at A(2B) and A(2A)ARs and a low efficacy partial agonist at A(1) and A(3)ARs. Thus, we have identified and optimized 2-(2-arylethyl) oxo moieties in AR agonists that enhance A(2B)AR potency and selectivity.

  DOI：

  10.1021/jm061278q
• 作为产物：
  描述：

  4-溴吲哚 、 草酰氯 以 乙醚 为溶剂， 反应 24.0h， 生成 2-(4-bromo-1H-indol-3-yl)-2-oxoacetyl chloride
  参考文献：
  名称：

  (±)-Communesin F的全合成

  摘要：

  复杂多环吲哚生物碱 (±)-communesin F 的全合成已在 23 个反应步骤中完成，总产率约为 3%。关键步骤依赖于用 C7 季碳组装五环亚结构 2 的高效方法，通过两步一锅 O-烯丙基化和连续 3,3-重排立体选择性制备第二个 C8 季碳（2到 3)，以及 4 的立体选择性酸催化环化形成氮杂环 (5)。这些高度立体选择性的反应保证了立体化学结果，允许构建 C、E、F 和 G 环系统。

  DOI：

  10.1021/ja075705g

文献信息

• DERIVATIVES OF AZA ADAMANTANE AND USES THEREOF
  申请人：CONNEXIOS LIFE SCIENCES PVT. LTD.

  公开号：US20150141650A1

  公开（公告）日：2015-05-21

  The present invention relates to certain amide derivatives that have the ability to inhibit 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and which are therefore useful in the treatment of certain disorders that can be prevented or treated by inhibition of this enzyme. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders. It is expected that the compounds of the invention will find application in the treatment of conditions such as non-insulin dependent type 2 diabetes mellitus (NIDDM), insulin resistance, obesity, impaired fasting glucose, impaired glucose tolerance, lipid disorders such as dyslipidemia, hypertension and as well as other diseases and conditions.

  本发明涉及某些酰胺衍生物，具有抑制11-β-羟基类固醇脱氢酶1型（11β-HSD-1）的能力，因此在预防或治疗可以通过抑制该酶而预防或治疗的某些疾病方面具有用处。此外，本发明涉及这些化合物、其制备方法、含有这些化合物的药物组合物以及这些化合物在治疗某些疾病中的用途。预计本发明的化合物将在治疗非胰岛素依赖型2型糖尿病（NIDDM）、胰岛素抵抗、肥胖、空腹血糖受损、糖耐量受损、脂质紊乱如血脂异常、高血压以及其他疾病和病症的治疗中发挥作用。
• Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles
  作者：Thomas A. Engler、Kelly Furness、Sushant Malhotra、Concha Sanchez-Martinez、Chuan Shih、Walter Xie、Guoxin Zhu、Xun Zhou、Scott Conner、Margaret M. Faul、Kevin A. Sullivan、Stanley P. Kolis、Harold B. Brooks、Bharvin Patel、Richard M. Schultz、Tammy B. DeHahn、Kashif Kirmani、Charles D. Spencer、Scott A. Watkins、Eileen L. Considine、Jack A. Dempsey、Catherine A. Ogg、Nancy B. Stamm、Bryan D. Anderson、Robert M. Campbell、Vasu Vasudevan、Michelle L. Lytle

  DOI：10.1016/s0960-894x(03)00461-x

  日期：2003.7

  The synthesis and CDK inhibitory properties of a series of indolo[6,7-a]pyrrolo[3,4-c]carbazoles is reported. In addition to their potent CDK activity, the compounds display antiproliferative activity against two human cancer cell lines. These inhibitors also effect strong G1 arrest in these cell lines and inhibit Rb phosphorylation at Ser780 consistent with inhibition of cyclin D1/CDK4.

  报道了一系列吲哚[6，7-a]吡咯并[3，4-c]咔唑的合成和CDK抑制性能。这些化合物除了具有强大的CDK活性外，还具有针对两种人类癌细胞系的抗增殖活性。这些抑制剂还影响这些细胞系中的强G1阻滞，并抑制Ser780处的Rb磷酸化，这与抑制细胞周期蛋白D1 / CDK4一致。
• Total Synthesis of (±)-Communesin F
  作者：Jun Yang、Haoxing Wu、Liqun Shen、Yong Qin

  DOI：10.1021/ja075705g

  日期：2007.11.1

  Total synthesis of the complex polycyclic indole alkaloid (±)-communesin F has been accomplished in 23 reaction steps in about 3% overall yield. The key steps relied on a highly efficient methodology for assembling the pentacyclic substructure 2 with the C7 quaternary carbon, the stereoselective preparation of the second C8 quaternary carbon by a two-step one-pot O-allylation and consecutive 3,3-rearrangement

  复杂多环吲哚生物碱 (±)-communesin F 的全合成已在 23 个反应步骤中完成，总产率约为 3%。关键步骤依赖于用 C7 季碳组装五环亚结构 2 的高效方法，通过两步一锅 O-烯丙基化和连续 3,3-重排立体选择性制备第二个 C8 季碳（2到 3)，以及 4 的立体选择性酸催化环化形成氮杂环 (5)。这些高度立体选择性的反应保证了立体化学结果，允许构建 C、E、F 和 G 环系统。
• BIS-INDOLIC DERIVATIVES, THEIR USES IN PARTICULAR AS ANTIBACTERIALS
  申请人：Denis Jean-Noël

  公开号：US20140228359A1

  公开（公告）日：2014-08-14

  The present invention relates to novel bis-indolic derivatives, processes for their preparation, and their potential use as new antibacterial drugs.

  本发明涉及新型双吲哚衍生物、其制备方法及其作为新型抗菌药物的潜在用途。
• Nickel-Mediated Inter- and Intramolecular C–S Coupling of Thiols and Thioacetates with Aryl Iodides at Room Temperature
  作者：Xiao-Bo Xu、Jian Liu、Jian-Jian Zhang、Ya-Wen Wang、Yu Peng

  DOI：10.1021/ol303366u

  日期：2013.2.1

  A Ni(0)-catalyzed intermolecular cross-coupling of various functionalized thiols and aryl Iodides has been developed and successfully extended to less explored intramolecular versions, where thioacetates could also be utilized as the strategic surrogate. Air-stable precatalysts, very mild conditions, and an easy protocol allow rapid access to medicinally useful aryl thioethers, as demonstrated in the facile synthesis of (+/-)-chuangxinmycin as a key step.